[e-mail]

Biotech Day In Review: Novartis Pulls Zelnorm Off The Market

Astellas is quite right : REGN has fantastic monoclonal technology. Rather than manipulate the Fc fragment, they know how to manipulate the moieties of the receptors linked to it. This is unique.
Have a look at a picture that hopefully makes this a bit more simple to understand :
www.healthvalue.net/VE...